Published in Future Oncol on April 01, 2007
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol (2008) 1.42
Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. Am J Cancer Res (2011) 1.13
MMP-7 is upregulated by COX-2 and promotes proliferation and invasion of lung adenocarcinoma cells. Eur J Histochem (2014) 0.89
TREM-1 is induced in tumor associated macrophages by cyclo-oxygenase pathway in human non-small cell lung cancer. PLoS One (2014) 0.84
HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway. Onco Targets Ther (2016) 0.80
Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Ann Thorac Surg (2006) 2.31
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol (2005) 2.48
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res (2006) 2.47
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res (2005) 2.32
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) (2011) 1.77
Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst (2009) 1.75
Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res (2005) 1.74
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med (2009) 1.60
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem (2002) 1.60
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer (2005) 1.59
Aromatase inhibitors in human lung cancer therapy. Cancer Res (2005) 1.55
Feasibility of retinoids for the treatment of emphysema study. Chest (2006) 1.45
Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res (2010) 1.44
Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res (2009) 1.43
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol (2008) 1.42
Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res (2013) 1.41
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res (2005) 1.37
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res (2003) 1.33
Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc (2008) 1.31
IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest (2002) 1.29
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol (2008) 1.28
Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat (2004) 1.22
CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci (2004) 1.18
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res (2006) 1.18
Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res (2004) 1.17
Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma. Clin Cancer Res (2009) 1.17
Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther (2007) 1.14
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol (2007) 1.13
IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol (2009) 1.12
Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res (2006) 1.12
CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol (2006) 1.12
SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer (2003) 1.11
Dietary flavonoid intake and lung cancer--a population-based case-control study. Cancer (2008) 1.10
Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res (2004) 1.09
Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging (2008) 1.08
IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res (2013) 1.07
Histopathologic findings of HPV and p16 positive HNSCC. Laryngoscope (2010) 1.07
Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites. Cancer Epidemiol Biomarkers Prev (2008) 1.06
COX-2 inhibition and lung cancer. Semin Oncol (2004) 1.06
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol (2014) 1.05
Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res (2006) 1.05
The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem (2006) 1.04
Evolving concepts in lung carcinogenesis. Semin Respir Crit Care Med (2011) 1.03
Recruitment strategies for a lung cancer chemoprevention trial involving ex-smokers. Contemp Clin Trials (2009) 1.03
EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. Am J Respir Cell Mol Biol (2007) 1.02
Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One (2011) 1.01
Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res (2004) 1.01
Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells. Lung Cancer (2011) 1.00
MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci U S A (2013) 1.00
Eosinophil and T cell markers predict functional decline in COPD patients. Respir Res (2009) 1.00
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther (2013) 0.99
Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol (2006) 0.98
Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J Immunol (2004) 0.98
EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol (2003) 0.97
CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer (2009) 0.97
IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity. J Immunol (2003) 0.96
Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila) (2014) 0.96
Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol (2008) 0.95
Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer (2005) 0.95
PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol (2005) 0.93
PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res (2010) 0.93
Snail as a novel marker for regional metastasis in head and neck squamous cell carcinoma. Am J Otolaryngol (2011) 0.93
Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer (2010) 0.93
Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis. J Biol Chem (2004) 0.92
IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun (2005) 0.91
Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol (2005) 0.91
Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood (2002) 0.91
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol (2013) 0.91
Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. Carcinogenesis (2010) 0.90
The role of ZEB1 in the inflammation-induced promotion of EMT in HNSCC. Otolaryngol Head Neck Surg (2010) 0.90
Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J (2003) 0.90
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest (2009) 0.90
A case-control study of the association of the polymorphisms and haplotypes of DNA ligase I with lung and upper-aerodigestive-tract cancers. Int J Cancer (2008) 0.89
The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenviron (2011) 0.89
Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem Biophys Res Commun (2002) 0.89
Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res (2011) 0.89
Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Hum Gene Ther (2003) 0.88
Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res (2013) 0.88
Soluble coxsackievirus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu. Clin Cancer Res (2002) 0.88
Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 0.88